| Indication | Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children up to 24 months of age at increased risk for severe RSV disease through their second RSV season |
| Drug | clesrovimab |
| Mechanism of Action | extended half-life monoclonal antibody |
| Company | Merck |
| Trial Phase | Phase 3 |
| Trial Acronym | SMART trial |
| NCT ID | NCT04938830 |
| Category | Regulatory Milestone |
| Sub Category | Approval Pending |
| Therapeutic Area | Respiratory |
| Regulatory Agency | CHMP, EMA, EC, U.S. FDA |
| Regulatory Outcome | Positive opinion for expanded indication, sBLA accepted |
| EU Marketing Authorization Region | European Union, Iceland, Liechtenstein, Norway |
| PDUFA Date | March 22, 2027 |
| Initial EU Approval Date | April 2026 |
| Initial US Approval Date | June 2025 |
| Target Patient Population | Children up to 24 months of age at increased risk for severe RSV disease through their second RSV season |
| Dosage for Second Season | 210 mg |
| Comparator in Trial | Palivizumab |
| Supporting Publications | New England Journal of Medicine, JAMA Pediatrics |
Merck's ENFLONSIA Receives Positive EU CHMP Opinion for Expanded RSV Indication
Merck announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of an expanded indication for ENFLONSIA® (clesrovimab). This expansion targets the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children up to 24 months of age who are at increased risk for severe RSV disease through their second RSV season. The recommendation will now be reviewed by the European Commission (EC) for marketing authorization in the EU, Iceland, Liechtenstein, and Norway, with a final decision expected within two months. ENFLONSIA was initially approved by the U.S. FDA in June 2025 and by the European Commission in April 2026 for infants in their first RSV season.
- The expanded indication addresses a critical unmet need for children up to 24 months of age who remain vulnerable to severe RSV in their second RSV season. This includes specific high-risk populations such as those born with chronic lung disease, congenital heart disease, or early/moderately preterm birth with certain risk conditions, who are susceptible to serious RSV-related bronchiolitis or pneumonia requiring hospitalization.
- The positive CHMP opinion is supported by comprehensive results from the Phase 3 SMART trial (MK-1654-007, NCT04938830). These pivotal data were presented at RSVVW’26, the 9th conference of the Respiratory Syncytial Virus Foundation (ReSViNET) in February 2026, and published in prestigious journals including the New England Journal of Medicine in September 2025 (interim results) and JAMA Pediatrics in July 2026 (full results).
- ENFLONSIA is already approved in over 55 countries worldwide, including the United States, Canada, China, Japan, and the European Union, for the prevention of RSV LRTD in infants during their first RSV season. It is notable as the first and only preventive option against RSV LRTD administered to infants without the need for weight-based dosing, offering direct, rapid, and durable protection. Regulatory filings for this expanded indication are also underway in the U.S. and other global markets.
Addressing the Persistent Vulnerability of Infants to Severe RSV
Respiratory syncytial virus (RSV) remains the leading cause of hospitalization in infancy and severe lower respiratory tract disease in early life, with the greatest vulnerability concentrated in preterm infants and those with underlying conditions. Prevention through the second RSV season in children up to 24 months of age focuses on populations at increased risk for severe disease who require extended protection beyond a single season.
Children aged ≤24 months who remain vulnerable to severe RSV disease through their second RSV season: Nirsevimab is approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season and in children aged ≤24 months who remain vulnerable to severe RSV disease through their second RSV season. The Centers for Disease Control and Prevention has recently recommended nirsevimab for all infants younger than 8 months of age entering or born during the RSV season and high-risk infants 8-19 months of age entering their second season.
Infants with congenital heart disease (CHD) and/or chronic lung disease of prematurity (CLD) or born ≤35 weeks' gestational age [wGA]: The Phase 2/3 MEDLEY (NCT03959488) trial enrolled infants with congenital heart disease [CHD] and/or chronic lung disease of prematurity [CLD] or born ≤35 wGA, with participants randomized 2:1 to receive a single intramuscular dose of nirsevimab or comparator (5× once-monthly palivizumab) before their first RSV season. In MEDLEY, children with CHD/CLD continued to a second RSV season: first-season nirsevimab recipients received nirsevimab 200 mg; first-season palivizumab recipients were re-randomized 1:1 to receive nirsevimab 200 mg or 5× once-monthly palivizumab.
Immunocompromised children aged ≤24 months: Immunocompromised children may have increased risk for severe respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI), potentially leading to prolonged hospitalization, intensive care, and death. The open-label phase II MUSIC trial evaluated nirsevimab, an extended half-life monoclonal antibody against RSV, in immunocompromised children aged ≤24 months with ≥1 immunocompromising conditions: primary immunodeficiency (n = 33), previous transplantation (n = 16), HIV infection (n = 8) or treatment with high-dose systemic corticosteroids (n = 29), immunosuppressive chemotherapy (n = 20), or other immunosuppressive therapies (n = 15).
Preterm infants and children with chronic lung disease / bronchopulmonary dysplasia (BPD), hemodynamically significant congenital heart disease, Down's syndrome, or immunodeficiency: Preterm infants, children with chronic lung disease of prematurity, Down's syndrome, congenital heart disease, or immunodeficiency also have a higher risk of severe RSV-LRTI. CLD/BPD is a significant independent risk factor for RSV hospitalization [RSVH (odds ratio 2.2-7.2)], with RSVH rates mostly varying between 12 and 21% and infants spending on average 4-11 days in hospital. Palivizumab protects high-risk newborns with comorbidities including chronic lung disease and congenital heart disease, but palivizumab is costly and requires monthly administration of up to five doses during the RSV season for optimal protection.
ENFLONSIA's Role in the Evolving RSV Prevention Landscape
For over two decades, palivizumab was the only monoclonal antibody available for RSV prophylaxis, restricted to high-risk groups due to cost and limited duration of protection. Palivizumab protects high-risk newborns with comorbidities including chronic lung disease and congenital heart disease, but requires monthly administration of up to five doses during the RSV season for optimal protection, administered as five once-a-month intramuscular doses of 15 mg/kg. Guidelines from the American Academy of Pediatrics recommend palivizumab immunoprophylaxis for children with chronic lung disease of prematurity in their second year of life if they continue to need treatment within 6 months before the RSV season.
The landscape shifted with nirsevimab, an extended half-life monoclonal antibody targeting the Ø antigenic site on the RSV prefusion protein and protecting infants from severe disease for an entire 5-month season with a single dose. In the MEDLEY phase 2-3 trial in infants at higher risk for severe RSV infection, nirsevimab showed a similar safety profile to that of palivizumab using a weight-banded regimen of 50 mg for infants weighing <5 kg and 100 mg for those weighing ≥5 kg followed by four monthly placebo doses. Pharmacokinetic extrapolation supported efficacy in infants with chronic lung disease, congenital heart disease, or extreme preterm birth (<29 weeks gestational age), with exposures above the target in more than 80% of the overall MEDLEY trial population (94%), including infants with chronic lung disease (94%) or congenital heart disease (80%) and those born extremely preterm (94%). In the open-label phase II MUSIC trial in immunocompromised children aged ≤24 months (n = 100), participants received a single intramuscular injection of nirsevimab (first RSV season: 50 mg if <5 kg/100 mg if ≥5 kg; second season: 200 mg), with six children experiencing eight treatment-related adverse events (none categorized as serious), three deaths all unrelated to treatment, eleven children developing antidrug antibodies with minimal effects on pharmacokinetics, serum concentrations at day 151 similar to those effective in preventing medically attended RSV lower respiratory tract infection in healthy infants, and no protocol-defined medically attended RSV lower respiratory tract infections through day 151. On August 3, 2023, the Advisory Committee on Immunization Practices recommended nirsevimab for infants and children aged 8-19 months who are at increased risk for severe RSV disease and are entering their second RSV season.
Most recently, clesrovimab (Enflonsia, MK-1654), a half-life extended monoclonal antibody targeting site IV of the RSV fusion protein, has generated second-season data in at-risk children. A population pharmacokinetic model from three infant studies estimated a half-life for clesrovimab of 44.0 days, with a geometric mean apparent half-life of 44.9 days in a phase 1b/2a trial of healthy preterm and full-term infants. The SMART (MK-1654-007) randomized, partially masked, palivizumab-controlled, phase 3 trial conducted at 110 sites in 27 countries between November 30, 2021, and November 20, 2025 enrolled palivizumab-eligible infants including those with prematurity, chronic lung disease of prematurity, or hemodynamically significant congenital heart disease, randomizing 1:1 to clesrovimab (105 mg) on day 1 followed by placebo on day 28 or monthly palivizumab (15 mg/kg) up to 5 doses, with eligible infants receiving open-label clesrovimab (210 mg) before their second RSV season. Overall, 997 infants (500 [50.2%] male; median age, 2.6 [range, 0.0-12.0] months) received clesrovimab 105 mg (n = 498) or palivizumab (n = 499) in season 1; 276 received clesrovimab 210 mg open-label in season 2. In season 1, proportions experiencing adverse events were comparable between groups, and in season 2, clesrovimab 210 mg was well tolerated. Incidence rates of RSV-associated medically attended lower respiratory infection were comparable between clesrovimab and palivizumab (3.2% [95% CI, 1.8%-5.2%] and 3.4% [95% CI, 2.0%-5.6%], respectively) through day 150 in season 1; total RSV-associated medically attended lower respiratory infection incidence through day 180 after a 210-mg dose in season 2 was 7.3% (95% CI, 4.4%-11.4%), supporting use in children who remain at risk for severe RSV disease in their second RSV season.
Frequently Asked Questions
References
- [1] Bizot E, Portet Sulla V et al.. Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in-depth review of mechanisms of action, failure factors, and future perspectives. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2025 Dec. 41347702
- [2] Munro APS, Drysdale SB et al.. 180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial. The Lancet. Child & adolescent health. 2025 Jun. 40379431
- [3] Hu Z, Hellmann F et al.. Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants. Clinical pharmacology and therapeutics. 2026 Apr. 41589687
- [4] Lekic E, Dragas L et al.. Effects of palivizumab prophylaxis on respiratory syncytial virus (RSV) infections in Montenegro. The Turkish journal of pediatrics. 2024 May 23. 38814297
- [5] Servadio M, Finocchietti M et al.. An epidemiological investigation of high-risk infants for Respiratory Syncytial Virus infections: a retrospective cohort study. Italian journal of pediatrics. 2024 Mar 25. 38528568
- [6] Razzini JL, Giné-Vázquez I et al.. Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study. The Lancet. Infectious diseases. 2026 May. 41539320
- [7] Newby B, Sorokan T. Respiratory Syncytial Virus Infection Rates with Limited Use of Palivizumab for Infants Born at 29 to 31+6/7 Weeks Gestational Age. The Canadian journal of hospital pharmacy. 2017 Jan-Feb. 28348428
- [8] Piñeros JG, De la Hoz-Valle J et al.. Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia. Journal of infection in developing countries. 2021 Nov 30. 34898500
- [9] Zar HJ, Bont LJ et al.. Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons: A Randomized Clinical Trial. JAMA pediatrics. 2026 Sep 1. 42475081
- [10] McPherson C, Lockowitz CR et al.. Balanced on the Biggest Wave: Nirsevimab for Newborns. Neonatal network : NN. 2024 Apr 1. 38599778
- [11] Paes B, Fauroux B et al.. Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Chronic Lung Disease. Infectious diseases and therapy. 2016 Dec. 27864751
- [12] Zar HJ. New advances in RSV: Is prevention attainable?. Pediatric pulmonology. 2025 Mar. 39466029
- [13] Jimeno Ruiz S, Peláez A et al.. Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain. Vaccines. 2024 Oct 11. 39460326
- [14] Phillips B, Jackson C et al.. Clesrovimab for the Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians. 2025 Nov 29. 41328290
- [15] Cheung A, Jain A et al.. Respiratory Syncytial Virus Immunization Disparities in Mothers and Infants at the Birth Hospitalization: A Cross-Sectional Study. The Journal of pediatrics. 2026 Oct. 42392501
- [16] Mao X, Hua X et al.. A phase I, randomized, placebo-controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults. Clinical and translational science. 2025 Jan. 39736101
- [17] Domachowske J, Hamrén UW et al.. Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children. Pediatrics. 2024 Oct 1. 39257380
- [18] Pavilack M, Clifford RA et al.. Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants. Infectious diseases and therapy. 2018 Mar. 29149439
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com














